DRP: Developmental Research Program

DRP：发展研究计划

• 批准号: 10713058
• 负责人: Alexander Olawaiye
• 金额: $ 11.09万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10713058
• 关键词: Advocate; Annual Reports; Application procedure; Area; Award; Bioinformatics; Biometry; Cancer Center; Cancer Research Project; Cessation of life; Clinical; Clinical Trials; Collaborations; Communities; Core Facility; Data; Development; Disease; Doctor of Philosophy; Early Diagnosis; Electronic Mail; Eligibility Determination; Ensure; Extramural Activities; Feedback; Financial Support; Fostering; Funding; Goals; Hospitals; Incubators; Individual; Infrastructure; Institution; Investments; Joints; Laboratories; Lead; Malignant Neoplasms; Malignant neoplasm of ovary; Mentors; Minority; Minority-Serving Institution; Monitor; Morbidity - disease rate; Outcome; Patients; Peer Review; Pilot Projects; Population; Population Sciences; Prevention; Process; Prognostic Marker; Program Research Project Grants; Progress Reports; Research; Research Personnel; Research Project Grants; Resources; Science; Scientist; Sister; Specimen; Testing; Tissues; Underrepresented Minority; United States National Institutes of Health; Universities; Vertebral column; Woman; Work; anticancer research; cohort; disability; equity, diversity, and inclusion; experience; flexibility; high reward; high risk; innovation; inter-institutional; meetings; member; minority investigator; mortality; mouse model; next generation; novel; outreach; peer; predictive marker; programs; recruit; repository; standard of care; success; therapy resistant; translational impact; tumorigenesis; web site

PROJECT SUMMARY – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The Developmental Research Program (DRP) of the UPMC Hillman Cancer Center (HCC) Ovarian Cancer SPORE seeks to fund and facilitate translationally-driven, innovative pilot projects in ovarian cancer. The overarching goal is to decrease ovarian cancer morbidity and mortality through stimulating new research in the areas of prevention and early detection; mechanisms of tumorigenesis and therapeutic resistance; predictive and prognostic biomarkers; and novel targets and approaches to therapy. An additional goal of the DRP is to establish support for underrepresented minorities in ovarian cancer research. To accomplish these goals, DRP will build on the successful program and infrastructure developed via a previous joint P50 award that resulted in an approximate 35-fold return on investment. The DRP will widely solicit proposals annually using local and national networks. To increase recruitment of underrepresented minorities to our DRP program, DRP will leverage University of Pittsburgh and HCC programs with Minority Serving Institutions to increase the participation of under-represented scientists. Additionally, members of the Internal and External Advisory Boards will be encouraged to identify investigators who could contribute to the diversity of the DRP. The most meritorious proposals will be selected based on an NIH-style two-tiered review to ensure rigor and absence of bias. The DRP Co-Directors, SPORE Executive Committee, Patient Advocates, and SPORE investigators will participate in the first-tier scientific review, together with ad hoc revewers when necessary. The final selection of awardees will be made following a second-tier programmatic review involving the SPORE Internal Advisory Board. Each award will provide $50,000 in funds, with half of the monies coming from the DRP and the other half from HCC, demonstrating substantial institutional commitment. DRP will fund three pilots per year, reserving one for an underrepresented minority investigator. DRP awardees new to ovarian cancer will be assigned an experienced mentor to provide guidance and integration into the SPORE. Awardees will be provided full access to the HCC Ovarian Cancer SPORE Core resources, including tissue specimens and bioinformatic/biostatistical support, not only to ensure project success but also to support subsequent funding applications outside the SPORE mechanism. All DRP awardees will meet bi-annually with the DRP Co- Directors, prepare progress reports annually, and make research presentations at SPORE meetings. Those that demonstrate significant research progress will be eligible for competitive renewal for a second year. Exceptional pilots with potential for significant translational impact can be elevated to full SPORE projects. The DRP provides a vital mechanism for achieving the SPORE’s goal of developing a diverse pool of ovarian cancer researchers committed to overcoming this deadly disease.

项目概要-药物研究中心（DRP） UPMC希尔曼癌症中心（HCC）的发展研究计划（DRP）卵巢癌 SPORE旨在资助和促进卵巢癌的预防性驱动的创新试点项目。的 总体目标是通过刺激对卵巢癌的新研究来降低卵巢癌的发病率和死亡率。 预防和早期发现领域;肿瘤发生和治疗耐药性的机制;预测 和预后生物标志物;以及新的靶点和治疗方法。DRP的另一个目标是 为卵巢癌研究中代表性不足的少数群体提供支持。为了实现这些目标，DRP 将建立在成功的计划和基础设施开发通过以前的联合P50奖，导致 大约35倍的投资回报。DRP每年将利用当地和 国家网络。为了增加我们DRP计划中代表性不足的少数民族的招聘，DRP将 利用匹兹堡大学和HCC计划与少数民族服务机构，以增加 代表性不足的科学家的参与。此外，内部和外部咨询委员会成员 将鼓励董事会确定可以为DRP的多样性做出贡献的研究人员。最 将根据NIH风格的两级审查选择有价值的提案，以确保严格性和不存在 bias. DRP联合董事、SPORE执行委员会、患者倡导者和SPORE研究者将 参加第一级科学审查，必要时与特设审查员一起参加。最终评选 获奖者的名单将在涉及SPORE内部咨询的第二级方案审查后确定。 纸板.每个奖项将提供5万美元的资金，其中一半来自DRP，另一半来自 其中一半来自总部合同委员会，表明了机构的重大承诺。DRP将每年资助三个试点项目， 为代表性不足的少数族裔调查员保留一名。DRP获奖者新卵巢癌将是 指派一名经验丰富的导师提供指导并将其整合到SPORE中。获奖者将 提供了对HCC卵巢癌SPORE核心资源的完全访问，包括组织标本， 生物信息/生物统计支持，不仅确保项目成功，而且支持后续资金 在SPORE机制之外的应用程序。所有DRP获奖者将每两年与DRP公司举行一次会议， 董事，每年准备进度报告，并在SPORE会议上做研究报告。那些 显示出重大研究进展的国家将有资格竞争性地延长第二年。 具有重大转化影响潜力的特殊试点项目可以提升为完整的SPORE项目。的 DRP为实现SPORE的目标提供了一个重要的机制，即开发一个多样化的卵巢储备库。 癌症研究人员致力于克服这种致命的疾病。